AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT00087594 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ribavirin
Description: 1000/1200mg (\< or >= 75 kg, respectively), po in two doses daily for 48 weeks (G 1) or 800 mg po in two doses daily for 24 weeks (G 2/3)
Study NCT01199744 — intervention group
Intervention type: DRUG
Intervention: zanamivir
Description: zanamivir
Study NCT00579956 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Meropenem
Description: Meropenem 1gm, diluted with 50ml normal saline solution IV every 8 hours for at least 10 days. The dose will be adjusted according to the creatinine clearance.
Study NCT01000467 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: probucol
Description: group 3: 250 mg 1 tablet in the morning and evening
Study NCT01000467 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: probucol
Description: group 1: 250 mg
Study NCT01000467 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: probucol
Description: group 2: 250 mg 2 tablets at once in the morning
Study NCT01489683 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: lidocaine
Description: 3 ml of 4% lidocaine was instilled to larynx and trachea
Study NCT00579956 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ceftazidime
Description: Ceftazidime 120mg/kg/day divided into 3 equal doses (maximum dose 2 gram/dose), diluted with 50ml normal saline solution IV every 8 hours for at least 10 days The dose will be adjusted according to the plasma creatinine level
Study NCT01433510 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Grazax
Description: 1 tablet/day - pre and co-seasonal
Study NCT06381752 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: Continuous passive motion
Description: Daily application of continuous passive motion
Study NCT00568750 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: dasatinib
Description: Dasatinib is given orally 70 mg BID. Dasatinib will be continued until progression, unacceptable toxicity and up to 2 years (26 cycles, each cycle lasting 4 weeks).
Study NCT01489683 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: normal saline
Description: 3 ml of normal saline was instilled to larynx and trachea before endotracheal intubation
Study NCT02877524 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Adaptive support ventilation
Description: ASV during NIV
Study NCT06381752 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: standard rehabilitation
Description: standard rehabilitation program with group physiotherapy
Study NCT02877524 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Pressure support ventilation
Description: PSV during NIV
Study NCT00454922 — intervention group
Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: standard of care
Description: no intervention
Study NCT00454922 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: education
Description: meet with trained glaucoma educator 6 times over life of study
Study NCT03489356 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Addressing Behavior Change (ABC)
Description: The ABC is a 3-minute brief, dermatologist delivered intervention for dermatological patients that takes place during a skin examination. During the ABC intervention, dermatologists specifically assess patients' UV risk behaviors, discuss patients' motivation to use UV protection, and explore solutions to patient-reported barriers interfering with effective sunscreen use. Based on our previous research, the ABC intervention does not add additional time to the visit, but rather replaces treatment as usual conversations about sun protection.
Study NCT03335059 — intervention group
Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: Synergo® RITE + MMC
Description: Subjects will receive a series of induction followed by a series of maintenance bladder instillations of Synergo® RITE + MMC
Study NCT02284711 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Bipolar electric energy
Description: Coagulation during salpingectomy using conventional bipolar electric energy
Study NCT02284711 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: ultrasound energy
Description: Coagulation during salpingectomy using UltraCision HARMONIC ACE® ultrasound energy
Study NCT00519935 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Multisystemic Therapy
Description: MST is an individualized approach that begins with a comprehensive, multi-informant assessment that allows for the development of treatment goals and interventions that are individually tailored for each family. Therapists draw upon a menu of evidenced-based interventions that include cognitive-behavioral therapy, parent training and behavioral family systems therapy.
Study NCT01156675 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: FLEXUS(TM) Interspinous Spacer
Description: Treatment of lumbar spinal stenosis with the FLEXUS™ Interspinous Spacer
Study NCT01156675 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: XSTOP® Interspinous Spacer
Description: Treatment of lumbar spinal stenosis with the XSTOP® Spacer
Study NCT00390845 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SB681323
Description: 15 milligrams (mg)/day
Study NCT00390845 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Study NCT01026207 — intervention group
Intervention type: DEVICE
Intervention: Polysomnography
Description: Sleep study polysomnography compared with portable monitoring
Study NCT00840775 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: Catheterization, stent deployment
Description: Standard catheterization procedure including Bare Metal Stent deployment.
Study NCT02617511 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Omega-3 Supplementation
Study NCT02617511 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study NCT02935608 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BIIB074
Description: Administered as specified in the treatment arm
Study NCT02935608 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Matched placebo
Study NCT01613625 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Elastography
Study NCT02030379 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: QPL-CT
Description: Use the QPL-CT to prioritize questions
Study NCT03629366 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Supported Employment (SE)
Description: Supported Employment
Study NCT03629366 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Treatment as usual (TAU)
Description: Treatment as usual
Study NCT00038038 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 18F-fluoromisonidazole
Description: Small amount of radioactive traces drug given by intravenous injection prior to PET Scan
Study NCT00043810 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fludarabine
Description: 40 mg/m2 in 100 ml of saline over one (1) hour on each of four (4) consecutive days (days - 6 to -3).
Study NCT03892603 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Strengthening exercises program
Description: Participants from this group will be given a progressive shoulder strengthening exercises program based on 1 RM that will involve isometric, concentric and eccentric contractions. The exercises will target shoulder internal/external rotators and abductors and the scapular muscles. They will have to exercise every other day for 12 weeks. At each session with the therapist (6 over a 12 week period), strength will be reassessed and the program will be progressed accordingly. Any questions or concerns will also be addressed and participants will be requested to complete a paper based or digital record of their exercise participation.
Study NCT00038038 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: PET scan
Description: Series of pictures using 20 minute scan performed 2 hours after an 18F-fluoromisonidazole injection
Study NCT03652519 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Exercise Training
Description: Treatment in both arms consists of specific of aerobic exercise training modalities. Exercise has become an efficient strategy within rehabilitative programs and is part of a goal-orientated multidisciplinary approach to improve disability and participation in persons with MS. Recently, short and exhaustive bouts of exercise have gained much attention as a promising option in supportive care in MS.
Study NCT03892603 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Motor control exercises program
Description: Each session will start with a series of clinical tests that will look at the influence of different corrections to alleviate symptoms during upper limb movements.The tests will be performed in a sequential format through four key areas: thoracic repositioning, scapula facilitation, humeral head procedures and neuromodulatory techniques. If a correction reduces pain, that technique will then be performed as exercises and incorporated into the participant's functional movement. In addition, motor control exercises during arm elevation, progressed through a standardized 6-phase retraining sequence, will be executed. Retraining phases will be graded according to: 1) resistance applied on the shoulder; and 2) use or non-use of feedback. Once participants reach pain free execution, the program will be progressed into re-education exercises according to the participants' work, sport and activities of daily living and will incorporate activities involving the upper and lower limbs.
Study NCT03892603 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Education and advice
Description: Each participant will be given written information about the shoulder (anatomy and function), basic pain science and will be directed to the Internet to watch a series of carefully selected educational videos. Comprehensive written advice will include: Information about the shoulder and the condition; Pain neuroscience; Activity modification (when to increase and decrease); Pain management (night and day); A series of educational videos to watch with 2 questions to answer per video: a) what was the most important message? and b) was there anything you didn't understand in the video?
Study NCT03652519 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Exercise Training
Description: Treatment in both arms consists of specific of aerobic exercise training modalities. Exercise has become an efficient strategy within rehabilitative programs and is part of a goal-orientated multidisciplinary approach to improve disability and participation in persons with MS. Recently, short and exhaustive bouts of exercise have gained much attention as a promising option in supportive care in MS.
Study NCT00278499 — intervention group
Intervention type: BEHAVIORAL
Intervention: Cross-sectional surveys
Description: Cross-sectional surveys will occur at study entry, Month 6, and Month 12. Every fourth participant enrolled in the FSW cross-sectional survey, all FSWs found to be HIV infected, and all FSWs who are intravenous drug users will participate in a substudy lasting 12 months.
Study NCT00278499 — intervention group
Intervention type: BEHAVIORAL
Intervention: Questionnaire/counseling
Description: An initial questionnaire and counseling will occur once in addition to post-test counseling.
Study NCT01738854 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: intracuff pressure by cuff pressure manometer
Description: 36 patients are randomly allocated according to random sequence of the intracuff pressure 40, 60 and 80 cmH2O. After insertion of LMA supreme, we confirm adequate ventilation. And then we measure OLP and leakage volume at intra-cuff pressure 40, 60 and 80 cmH2O adjusted by cuff pressure manometer according to random sequence of the intracuff pressure.
Study NCT01738854 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: intracuff pressure by cuff pressure manometer
Description: 36 patients are randomly allocated according to random sequence of the intracuff pressure 40, 60 and 80 cmH2O. After insertion of LMA supreme, we confirm adequate ventilation. And then we measure OLP and leakage volume at intra-cuff pressure 40, 60 and 80 cmH2O adjusted by cuff pressure manometer according to random sequence of the intracuff pressure.
Study NCT02003950 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Snack Condition Specification
Description: Individuals recieve a different snack for every week of the study. This is viewed as 4 phases. Phase 1 measures of habitual chocolate candy consumption (1 week), Phase 2 assesses participants' chocolate consumption while anticipating an oncoming chocolate candy restriction (1 week), Phase 3 is the total chocolate candy restriction period, but participants will be given 3 non-chocolate-candy snack substitutes in a random order (1 week per snack type, 3 weeks total), and Phase 4 examines participants' chocolate candy consumption when the 3-week restriction is lifted (1 week).
Study NCT03754712 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Vitamin D3
Description: Dietary supplement : Vitamin D3 one tablet of vitamin D3 (2000IU) per day for 8 weeks
Study NCT03501758 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Ultrasound
Description: Transabdominal ultrasound of the bowel for categorisation of disease activity
Study NCT03501758 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Analysis of prouroguanyline and uroguanyline in full blood
Description: Withdrawal of full blood at each study visit, Storage in biobank. Analysis of prouroguanyline and proguanyline.
Study NCT01265849 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: LI
Description: LI 400 IU (2.0mL total daily) 1.0 mL peritumoral, 1.0 mL perilymphatic 5x weekly x3 consecutive weeks administered as neoadjuvant therapy prior to SOC, (surgery followed by radiation or concurrent radiochemotherapy with cisplatin 100 mg/m\^2 intravenously x3) to determine if LI plus CIZ affects the 3-5 year overall survival.
Study NCT01265849 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide
Description: Cyclophosphamide was administered IV bolus (one time only) at a dose of 300mg/m\^2 three days prior to beginning treatment with LI. Standard of care (SOC) for previously untreated squamous cell carcinoma of the head and neck is currently surgery followed by radiotherapy (60-70Gy in 30 to 35 fractions over 6 to 7 weeks) for higher risk subjects (subjects determined at surgery to have adverse features per the National Comprehensive Cancer Network (NCCN) guidelines, such as, positive surgical margins, 2 or more clinically positive nodes or extracapsular nodal spread, etc. that would pre-dispose them for higher risk of recurrence) radiotherapy is combined with concurrent chemotherapy (cisplatin 100mg/m\^2 intravenously on day 1 of weeks 1, 4 and 7 of radiotherapy.
Study NCT00442455 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Erlotinib chlorhydrate
Description: 150 mg/day for 7 weeks
Study NCT00442455 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cisplatin
Description: 30 mg/m2 i.v. weekly for 7 weeks
Study NCT01265849 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Indomethacin
Description: One 25mg capsule of indomethacin was self administered orally (BID) beginning on day one of LI treatment daily until the day before surgery.
Study NCT01265849 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Zinc
Description: One capsule daily self administered beginning on day one of treatment with LI until one day before surgery
Study NCT01265849 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Surgery
Description: Excise tumor and nodes
Study NCT01265849 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Surgery
Description: Excise tumor and nodes
Study NCT01265849 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cisplatin
Description: Cisplatin was administered 100mg/m\^2 IV concurrent with radiotherapy. The chemotherapy agent (cisplatin 100mg/m\^2) was administered intravenously on day 1 of weeks 1, 4 and 7 of radiotherapy.
Study NCT01265849 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Cisplatin
Description: Cisplatin was administered 100mg/m\^2 IV concurrent with radiotherapy. The chemotherapy agent (cisplatin 100mg/m\^2) was administered intravenously on day 1 of weeks 1, 4 and 7 of radiotherapy.
Study NCT01265849 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Radiotherapy
Description: Total 60 to 70 Gy (2Gy per day) in 30 to 35 fractions over 6 to 7 weeks to subjects determined at surgery to be at lower risk for recurrence (per NCCN guidelines). For subjects determined at surgery to be at higher risk for recurrence due to having positive surgical margins, 2 or more clinically positive nodes or extracapsular nodal spread etc. (per NCCN guidelines), radiotherapy (as above) is combined with concurrent chemotherapy (cisplatin 100 mg/m\^2) intravenously on day 1 of weeks 1, 4 and 7 of radiotherapy.
Study NCT03304067 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Tueo Program
Description: The asthma management solution utilizes devices (2 to attach on the child's bed and 1 for data transmission), which collect various metrics for a tailored smartphone application experience. The smartphone application provides access to view metrics from the devices, educational and clinical context content, and an asthma coach.
Study NCT01264614 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Strengthening exercise
Description: 3 months of 3-5 times per week of low-intensity exercises using a chair and small weights
Study NCT01264614 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Strengthening exercise
Description: 3 months of 3-5 times per week of low-intensity exercises using a chair and small weights
Study NCT02792998 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: IW-1701
Description: IW-1701 Tablet
Study NCT02792998 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Matching Placebo Tablet
Study NCT02391532 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: L. reuteri DSM 17938/ATCC PTA
Description: Ingestion of active lozenge twice daily for 12 weeks
Study NCT02391532 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Ingestion of placebo lozenge twice daily for 12 weeks
Study NCT01265849 — intervention group
Intervention type: RADIATION
Group type: ACTIVE_COMPARATOR
Intervention: Radiotherapy
Description: Total 60 to 70 Gy (2Gy per day) in 30 to 35 fractions over 6 to 7 weeks to subjects determined at surgery to be at lower risk for recurrence (per NCCN guidelines). For subjects determined at surgery to be at higher risk for recurrence due to having positive surgical margins, 2 or more clinically positive nodes or extracapsular nodal spread etc. (per NCCN guidelines), radiotherapy (as above) is combined with concurrent chemotherapy (cisplatin 100 mg/m\^2) intravenously on day 1 of weeks 1, 4 and 7 of radiotherapy.
Study NCT02716558 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: ART Sealant Application
Description: application of the ART sealant using high viscosity glass inomer cements.
Study NCT02716558 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Resin sealant application
Description: application of the moisture tolerant sealant according to the manufacturers instructions.
Study NCT03371992 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Nivolumab
Description: Nivolumab, pembrolizumab or atezolizumab will be administered as per the established standard of care for the eligible population.
Study NCT03371992 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: OTHER
Intervention: 3D-EX
Description: Analysis of drug-mediated changes in the tumor microenvironment.
Study NCT03371992 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Evaluation of Response by RECIST
Description: Evaluation of tumor response using the set of published rules to determine if a tumor has responded, is stable or progressed during treatments.
Study NCT00405873 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AMT2003
Study NCT02192255 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Intervention Phone Call
Description: The intervention arm consisted of one protocol-structured telephone call from an interventionist who was a nurse health manager (1 site), diabetes educator or diabetes educator trainee (1 site), or pharmacist (2 sites). Interventionists followed the same structured telephone interview protocol to ascertain whether the subject had started taking the new prescription. Those taking the new medication as prescribed received positive reinforcement. Those who either had not filled the prescription or were not taking the medication as directed, were asked about reasons for nonadherence and assisted in identifying and resolving barriers. The median call lasted \< than 5 minutes, and up to 3 call attempts were made. Most intervention calls occurred within 2 to 6 weeks after the prescription date.
Study NCT02608931 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dronabinol
Study NCT02608931 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: placebo
Study NCT04152824 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Resilience-Supportive Leadership Training (RESULT)
Description: Leaders will receive a training addressing supportive supervisor behaviors and resilience